8-K: PDS Biotechnology Corp. CFO Resigns, Interim Appointed

PDS Biotechnology Corporation announced the resignation of its Chief Financial Officer, Lars Boesgaard, effective September 12, 2026, with interim appointments made for the Principal Financial and Accounting Officer roles.

Summary

• Lars Boesgaard has resigned as CFO, Principal Financial Officer, and Principal Accounting Officer of PDS Biotechnology Corporation, with his resignation effective September 12, 2026.
• The resignation is due to Mr. Boesgaard pursuing other professional endeavors and is not related to any disagreements with the Company's operations, policies, or practices.
• Janetta Trochimiuk, the Company's Controller, has been appointed interim Principal Accounting Officer.
• Frank Bedu-Addo, Ph.D., President and CEO, has been appointed interim Principal Financial Officer.
• Both interim appointments are effective September 12, 2026.
• Ms. Trochimiuk, age 63, has over 25 years of experience as a Controller or CFO and will continue her current base salary of $279,519.57.
• No equity awards were granted to Ms. Trochimiuk in connection with her interim appointment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, primarily an administrative change in financial leadership without immediate operational or strategic implications.

Positives

• The departure of the CFO is not due to any disagreements, indicating a smooth transition.
• Interim appointments are in place to ensure continuity in financial leadership.
• Janetta Trochimiuk, the interim Principal Accounting Officer, has extensive experience (over 25 years) in financial roles.
• The company has a clear succession plan for interim financial leadership.

Negatives

• The company is losing its Chief Financial Officer, which can sometimes lead to a period of adjustment.
• The need for interim appointments suggests a lack of a permanent successor ready to step in.

Risks

• Potential for a temporary disruption in financial operations or strategy during the transition period.
• The interim nature of the appointments may create uncertainty for investors regarding long-term financial leadership.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing regarding future financial performance or strategy. The focus is on the executive transition.

Management Comments

• Lars Boesgaard's resignation is to pursue other professional endeavors.
• Mr. Boesgaard acknowledged that his resignation is not the result of any disagreement relating to Company's operations, policies or practices.

Industry Context

StockSavvy.ai notes that executive transitions, particularly in financial roles, are common in the biotechnology sector due to its dynamic nature and the high demands placed on leadership. Ensuring continuity in financial oversight is critical for maintaining investor confidence.

Management Changes

Stakeholder Impact

• Shareholders: May experience a brief period of uncertainty regarding financial leadership, though the smooth transition and experienced interim appointments should mitigate significant impact.
• Employees: May experience a period of adjustment to new interim financial leadership.
• Creditors/Suppliers: Unlikely to be significantly impacted given the interim appointments and lack of stated disagreements.

Next Steps

• The company will operate with interim Principal Financial and Accounting Officers starting September 12, 2026.
• The board of directors will likely seek a permanent replacement for the CFO position.

Key Dates

Recommendation

The filing details a routine executive transition for the CFO role. While the departure itself is noted, the lack of any negative reasons for departure and the immediate appointment of experienced interim officers suggest business continuity. This event alone does not provide sufficient new information to warrant a change in investment strategy, thus a 'hold' recommendation is appropriate pending further developments.

Keywords

CFO Resignation, Interim Appointment, Financial Officer, Accounting Officer, Corporate Governance, Executive Transition